Ligandrol (LGD-4033)
LGD-4033 · LGD · Anabolicum
Potent SARM for lean mass; suppression evident at higher doses.
Key takeaways
- Phase 1 trial showed dose-dependent lean mass gains at 0.1–1 mg daily over 21 days.
- Roughly 30-hour half-life and 60% oral bioavailability support once-daily dosing.
- Suppression of testosterone and HDL becomes pronounced at common off-label doses.
- Unapproved, WADA-prohibited, and frequently mislabeled in grey-market products.
Reported dosing protocols
Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.
| Use case | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Clinical trial (phase 1) | 0.1–1 mg | Oral | Once daily | 21 days |
| Physique (community) | 2–10 mg | Oral | Once daily | 6–8 weeks |
Pharmacokinetic summary
- Model tier
- Advanced (t½ + Cmax + Tmax + F)
- Half-life
- 30 hours
- Cmax
- 498 ng/mL
- Tmax
- 0.1 days
- Bioavailability
- 60%
- Typical dose
- 2–10 mg
Harm reduction
- Aromatizes
- No
- Hepatotoxicity
- mild
- Injection frequency
- Oral, daily
Frequently asked questions
Is LGD-4033 approved for anything?
No. Development stopped after early-phase trials and it has no approved use. It's prohibited by WADA, and grey-market products sold as LGD-4033 are often mislabeled or contaminated, per anti-doping analyses.
How suppressive is ligandrol?
The phase 1 trial showed dose-dependent drops in free testosterone and SHBG after 21 days at 1 mg, reversing after discontinuation. Off-label doses run several times higher, so expect suppression and plan bloodwork and PCT accordingly.
Ligandrol vs ostarine — what's the difference?
Ligandrol is more potent per milligram with published phase 1 PK data (30-hour half-life), while ostarine has phase 2 efficacy data but weaker per-mg effects. Both are unapproved and WADA-prohibited; neither has safety data at community doses.
References
- PMC LGD-4033 PK — Tmax/Cmax estimated from 1 mg graph.
- Basaria et al., J Gerontol A 2013 — phase 1 trial — Ascending-dose safety, PK, and lean mass data at 0.1–1 mg daily for 21 days.
Related compounds
Ostarine (MK-2866 / Enobosarm)
Non-steroidal SARM; mild, used in cutting/recomp. Simple model (estimated).
Andarine (S4)
SARM with notable vision-related side effects; short half-life requiring divided dosing.
Testolone (RAD-140)
Potent SARM; suppression and hepatotoxicity reported at higher doses.
Protocols featuring Ligandrol (LGD-4033)
Comments
Loading comments…